# Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.

> **NCT06440057** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 78 (estimated)

## Conditions studied

- Neuroendocrine Carcinoma

## Interventions

- **BIOLOGICAL:** ZG006

## Key facts

- **NCT ID:** NCT06440057
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-29
- **Primary completion:** 2026-05
- **Final completion:** 2026-07
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06440057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06440057, "Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06440057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*